• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC SOFAMOR DANEK USA, INC. INFUSE BONE GRAFT; FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC P

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC SOFAMOR DANEK USA, INC. INFUSE BONE GRAFT; FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC P Back to Search Results
Model Number MSB_UNK_BMP2_ACS
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Wound Dehiscence (1154)
Event Date 06/28/2021
Event Type  Injury  
Event Description
Information was received from a health care professional via clinical study regarding a patient with clinical id: (b)(6).Primary diagnostic indication: stenosis with documented pre_operative instability from l2-s1.The subject will have treated: 2 levels.Currently consume alcohol, tobacco use ex-user.It was reported that the patient had wound dehiscence.Onset date (b)(6) 2021.  (b)(6) 2021 wound drainage- tx 2wk prophylaxis- keflex;  (b)(6) 2021 cont wound drainage & non healing of upper portion of wound-started patient on bactrim & planned exploratory surgery for (b)(6) 2021;  (b)(6) 2021 admitted for planned exploratory surgery- wound wash out, debridement & wound closured to home (b)(6) 2021.  (b)(6) 2021- (b)(6) visit for incisional leakage of clear yellow drainage, non purulent- nsgy consult- wound oversewn in (b)(6) & pt discharged to home.  (b)(6) 2021 wc- persistant drainage, stitches left in, started bactrim ds for prophylaxis.(b)(6) 2021 wound healed/looks good w/ no sign of infection.Interventions: drug therapy, hospitalization (date of admission: (b)(6) 2021 & date of discharge: (b)(6) 2021), surgical intervention.Length of hospitalization: less than or equal 24h prolongation of existing hospitalization: no there was no patient involvement/symptom reported.There were no further complications reported. outcome status resolved  outcome date (b)(6) 2021 assignment: 4.2 mg of rhbmp-2 randomization date: (b)(6) 2021  number of levels to be treated: 2 levels  pregnant since last visit 6_weeks: has the subject become pregnant since last visit: na date of visit: (b)(6) 2021  pregnant since last visit 3_months: has the subject become pregnant since last visit: na date of visit: (b)(6) 2021 site seriousness assessment: medical intervention: y site related assessment: possible to be related to plf grafting material & surgical procedure and related to surgical construct and/or study procedure.Sponsor assessment: possibly related to infuse kit, mgs kit and casual relationship with surgical procedure.Usade/uade assessment: no could dd have led to sade?: not applicable surgical procedure: date: (b)(6) 2021 treatment group: group 1 - infuse 4.2 + mastergraft + local bone.Updated information received on (b)(6) 2021: additional surgery: procedure date: (b)(6) 2021 describe the additional surgical procedure: wound exploration surgery-wound revision, irrigation, debridement and closure of wound.Index surgery was (b)(6) 2021.Patient was discharged to home on (b)(6) 2021.Levels involved in additional surgical procedure: non-target/non-lumbar level specify the relatedness of the additional surgical procedure to surgical construct and/or the study procedure: related plf grafting material related to surgical construct and/or surgical procedure: possible posterior fixation related to surgical construct and/or surgical procedure: unlikely interbody fusion related to surgical construct and/or surgical procedure: unlikely surgical procedure related to surgical construct and/or surgical procedure: possible.
 
Manufacturer Narrative
Neither the device nor films of applicable imaging studies were returned to the manufacturer for evaluation.Therefore, we are unable to determine the definitive cause of the reported event.If information is provided in the future, a supplemental report will be issued.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INFUSE BONE GRAFT
Type of Device
FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC P
Manufacturer (Section D)
MEDTRONIC SOFAMOR DANEK USA, INC.
1800 pyramid place
memphis TN 85281
Manufacturer (Section G)
MEDTRONIC SOFAMOR DANEK USA, INC.
1800 pyramid place
memphis TN 85281
Manufacturer Contact
glen belmer
1800 pyramid place
memphis, TN 38132
6122713209
MDR Report Key12877303
MDR Text Key282609251
Report Number1030489-2021-01462
Device Sequence Number1
Product Code NEK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P000054
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 11/26/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/26/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberMSB_UNK_BMP2_ACS
Device Catalogue NumberMSB_UNK_BMP2_ACS
Device Lot NumberMDC4314AAA
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/04/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention; Hospitalization;
Patient Age52 YR
Patient SexMale
Patient Weight99 KG
Patient EthnicityNon Hispanic
Patient RaceWhite
-
-